Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1YHL

Structure of the complex of Trypanosoma cruzi farnesyl diphosphate synthase with risedronate, dmapp and mg+2

Summary for 1YHL
Entry DOI10.2210/pdb1yhl/pdb
Related1YHK
Descriptorfarnesyl pyrophosphate synthase, MAGNESIUM ION, SULFATE ION, ... (6 entities in total)
Functional Keywordsfarnesyl diphosphate synthase, bisphosphonate, dimethyl allyl pyrophosphate sulfate, fpps, transferase
Biological sourceTrypanosoma cruzi
Total number of polymer chains1
Total formula weight41923.51
Authors
Gabelli, S.B.,McLellan, J.S.,Montalvetti, A.,Oldfield, E.,Docampo, R.,Amzel, L.M. (deposition date: 2005-01-09, release date: 2005-12-20, Last modification date: 2024-02-14)
Primary citationGabelli, S.B.,McLellan, J.S.,Montalvetti, A.,Oldfield, E.,Docampo, R.,Amzel, L.M.
Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: Implications for drug design.
Proteins, 62:80-88, 2005
Cited by
PubMed Abstract: Typanosoma cruzi, the causative agent of Chagas disease, has recently been shown to be sensitive to the action of the bisphosphonates currently used in bone resorption therapy. These compounds target the mevalonate pathway by inhibiting farnesyl diphosphate synthase (farnesyl pyrophosphate synthase, FPPS), the enzyme that condenses the diphosphates of C5 alcohols (isopentenyl and dimethylallyl) to form C10 and C15 diphosphates (geranyl and farnesyl). The structures of the T. cruzi FPPS (TcFPPS) alone and in two complexes with substrates and inhibitors reveal that following binding of the two substrates and three Mg2+ ions, the enzyme undergoes a conformational change consisting of a hinge-like closure of the binding site. In this conformation, it would be possible for the enzyme to bind a bisphosphonate inhibitor that spans the sites usually occupied by dimethylallyl diphosphate (DMAPP) and the homoallyl moiety of isopentenyl diphosphate. This observation may lead to the design of new, more potent anti-trypanosomal bisphosphonates, because existing FPPS inhibitors occupy only the DMAPP site. In addition, the structures provide an important mechanistic insight: after its formation, geranyl diphosphate can swing without leaving the enzyme, from the product site to the substrate site to participate in the synthesis of farnesyl diphosphate.
PubMed: 16288456
DOI: 10.1002/prot.20754
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.95 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon